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Dendritic cells (DC) in the spleen are highly activated following intravenous vaccination with
a foreign-antigen, promoting expansion of effector T cells, but remain phenotypically and
functionally immature after vaccination with a self-antigen. Up-regulation or suppression
of expression of a cohort of pancreatic enzymes 24–72 h post-vaccination can be used
as a biomarker of stimulatory versus tolerogenic DC, respectively. Here we show, using
MUC1 transgenic mice and a vaccine based on the MUC1 peptide, which these mice per-
ceive as a self-antigen, that the difference in enzyme expression that predicts whether DC
will promote immune response or immune tolerance is seen as early as 4–8 h following
vaccination. We also identify early production of IL-10 as a predominant factor that both
correlates with this early-time point and controls DC function. Pre-treating mice with an
antibody against the IL-10 receptor prior to vaccination results in DC that up-regulate CD40,
CD80, and CD86 and promote stronger IFNγ+ T cell responses. This study suggests that
transient inhibition of IL-10 prior to vaccination could improve responses to cancer vaccines
that utilize self-tumor antigens.
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INTRODUCTION
The impact of IL-10 on the cells of the immune system is well
studied and varied. Originally identified as cytokine synthesis
inhibitory factor, IL-10 can play a role in the development and
maturation of almost all immune cells (1, 2). Signaling through
the IL-10 receptor (IL-10R) occurs through a STAT3 intermediate
and is known to induce SOCS-3 expression, to suppress IFN sig-
naling by blocking STAT1 phosphorylation, and to inhibit NF-κB
signaling by preventing its nuclear translocation as well as inhibit-
ing its binding to DNA (2, 3). In dendritic cells (DC), known for
being the most important professional antigen presenting cells, IL-
10 can reduce expression of MHC Class II and the costimulatory
molecules CD80/86 and CD40, as well as reduce IL-12 secretion
(3–6). This is true even for DC previously activated with IFNγ.
IL-10 can also prevent monocyte differentiation into DC (2).
IL-10 has a profound effect on T cells as well. For example,
reduced IL-12 production by DC affected by IL-10 antagonizes
the development of T helper type 1 (Th1) responses while reduced
MHC II levels on DC result in presentation of low density antigen
that preferentially stimulates differentiation of regulatory CD4 T
cells (7, 8). IL-10 can also act directly on T cells to inhibit synthesis
of cytokines like IL-2 and IFNγ in CD4 T cells or to inhibit their
proliferation (3). The effect of IL-10 on CD8 T cells is less clear
although some studies have shown that IL-10 can favor activation
of CD8 T cells (9–11).
Recently, our group implicated IL-10 in controlling in part the
function of DCs post-vaccination with antigens derived from self-
proteins. Using the MUC1 transgenic (MUC1.Tg) mouse model
and a peptide derived from the extracellular domain of the tumor
antigen MUC1, we showed that 24 h following vaccination, there is
an IL-10 dependent suppression of DC activation that is detectable
via suppression of expression of a newly discovered biomarker: a
cohort of pancreatic enzymes. These enzymes, expressed in the
spleen only by DC and represented by trypsin 1 and carboxypepti-
dase B1 (CPB1), are up-regulated post-vaccination with a foreign
but not a self-antigen and identified a DC population that has
higher MHC Class II, higher costimulatory molecule expression,
and a higher T cell stimulatory capacity (12).
In this study, we present new evidence of an important role
for IL-10 in the suppression of splenic DC following intravenous
vaccination with a self-antigen. We show an early (4–8 h) up-
regulation in IL-10 levels in spleens of self-antigen vaccinated
mice that is not seen in mice that see that same antigen as for-
eign and coincides with the time when we also see differences in
biomarker enzyme expression. Furthermore, DC in the spleens of
self-antigen vaccinated mice have an increased sensitivity to IL-10.
When the effect of IL-10 is blocked by pre-vaccination treatment
of mice with an anti-IL-10R blocking antibody, there is a signifi-
cant increase in the activation level and stimulatory capacity of DC
at 24 h post-vaccination and a significant increase in CD4 T cell
responses 7 days post-vaccination. These data implicate IL-10 in
the regulation of antigen-specific immunity versus tolerance at a
previously underappreciated early time post-vaccination, and sug-
gest that manipulating its function at the time of vaccination might
overcome tolerance and improve responses to cancer vaccines that
utilize self-antigens.
MATERIALS AND METHODS
MICE
Human MUC1.Tg mice (13) on the C57Bl/6 background were a
generous gift from Dr. Sandra Gendler (Mayo Clinic) and were
bred and maintained in the University of Pittsburgh Animal
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Facility. C57Bl/6 (WT) mice were purchased from The Jackson
Laboratory. All experiments were approved by the Institutional
Animal Care and Use Committee of the University of Pittsburgh.
MUC1 VACCINATION
A 100-aa peptide containing five repeats of the MUC1 VNTR
sequence HGVTSAPDTRPAPGSTAPPA, was synthesized as previ-
ously described (14) by the University of Pittsburgh Genomics and
Proteomics Core Laboratories. For soluble peptide vaccinations,
100µg of this 100mer peptide admixed with 50µg polyinosinic–
polycytidylic acid and poly-l-lysine (Poly-ICLC; Hiltonol) was
brought up to 100µL with PBS and injected via tail vein. For
DC-based vaccinations, DC were prepared as previously described
(15). Briefly, RBC lysed bone marrow cells were put into cul-
ture for 6 days in AIM-V supplemented with 10 ng/mL GM-CSF
(Miltenyi), feeding once on day 3. On day 6, semi-adherent
cells were collected by gentle agitation and put into culture
overnight in AIM-V containing 33µg/mL MUC1 100mer pep-
tide and 25µg/mL Poly-ICLC. The next day, mature DC were
collected and resuspended in PBS at a final concentration of
0.5−1× 106 cells/mL. One hundred microliters of this solution was
then injected intravenously via tail vein.
IL-10R BLOCKADE
Where indicated, mice were given 250µg of an antibody against
the IL-10R (Bio X Cell, Clone 1B1.3A) or an isotype-matched
control antibody (Bio X Cell, Clone HPRN), intraperitoneally.
Twenty-four to forty-eight hours following treatment, mice were
vaccinated as described in “MUC1 vaccination” above and ana-
lyzed as described.
QUANTITATIVE RT-PCR
RNA was extracted from whole spleen using TRIzol (Invitrogen)
according to the manufacturer’s protocol. Following extraction,
cDNA was generated using oligo(dT) primers and SuperScript
III reverse transcriptase (Invitrogen). qPCR was performed using
QuantiTect SYBR Green PCR kit (Qiagen) according to the man-
ufacturer’s protocol. Reactions were run on a StepOnePlus instru-
ment (Applied Biosystems). The following primer pairs were
used: trypsin 1 (forward: 5′ACTGTGGCTCTGCCCAGCTC3′;
reverse: 5′AGCAGGTCTGGTTCAATGACTGT3′), CPB1 (for-
ward: 5′GCCCTGGTGAAAGGTGCAGCAAAGG3′; reverse: 5′AG
CCCAGTCGTCAGATCCCCCAGCA3′), IL-10 (forward: 5′CTTC
CCAGTCGGCCAGAGCCA3′; reverse: 5′ CTCAGCCGCATCCTG
AGGGTCT3′), and HPRT (forward: 5′TGAGCCATTGCTGAGGC
GGCGA3′; reverse: 5′CGGCTCGCGGCAAAAAGCGGTC3′).
INTRACELLULAR CYTOKINE STAINING/FLOW CYTOMETRY
For ex vivo T cells assays, 7–9 days post MUC1 vaccination, mice
were sacrificed and spleens were removed. Single-cell suspen-
sions were made by mashing the spleens through a 40-µm fil-
ter. Total T cells were then bead isolated (Pan T Cell Isolation
Kit II, Miltenyi) and cultured with day 6 MUC1-loaded BMDC
(prepared as described in “MUC1 vaccination”) for 4–6 h in the
presence of GolgiStop (BD biosciences). Cells were then stained
with the indicated antibodies using the BD Cytofix/Cytoperm™
kit (BD Bioscience) according to the manufacturer’s proto-
col. All samples were run on a Fortessa (BD bioscience) flow
cytometer and analyzed using FACSDiva (BD Bioscineces) and
FlowJo software (Tree Star Inc.). Antibodies used: CD3-PerCP,
CD11c-BV421, CD80-FITC, CD86-APC/Cy7, CD40-APC, CD3-
PeCy5, CD4-V450, CD8-AF700, IFNγ-PeCy7, TNFα-PE, IL-2-
APC, CD44-FITC, CD3-APC/Cy7, and CD8 PerCP.
PHOSPHOFLOW
Twenty-four hours following MUC1 vaccination, splenocytes were
harvested as above. Post isolation, cells were put into AIM-V
with or without 30 ng/mL IL-10 (PeproTech) for 20 min. At the
end of culture, cells were immediately fixed in 1.6% PFA for
10 min at room temperature. After 10 min, four volumes of ice-
cold methanol were added and samples were stored at −80°C.
At the time of staining cells were put at room temp for 10 min
and then immediately spun down and resuspended in flow buffer
(PBS containing 1% BSA, 0.02% sodium azide, and 2 nM EDTA).
After 10 min incubation at room temperature, cells were spun
down and washed with flow buffer twice. Samples were then
stained with antibodies against cell surface antigens CD11c,NK1.1,
and CD3 and phospho-specific anti-pSAT3 antibody for 1 h at
room temperature and prepared for analysis via standard proto-
col and as described above. Antibodies used: CD11c-Pacific Blue,
pSTAT3-AF647, NK1.1-PE, and CD3-APC/Cy7.
EX VIVO DC STIMULATORY CAPACITY ANALYSIS
MUC1 transgenic mice were pretreated with antibodies and vac-
cinated as in “IL-10R Blockade.” Post-vaccination, DC were bead
isolated (CD11c MicroBeads, Miltenyi) from the spleens of the
vaccinated animals. These DC were put into culture with bead iso-
lated (CD4 T cell Isolation Kit II, Miltenyi) CFSE stained MUC1
specific VFT CD4 T cells (15) at a ratio of 1 DC to 5 VFT cells in
complete DMEM. Twenty-four hours after the start of culture half
of the media was removed and saved for cytokine analysis. IL-2
was analyzed by ELISA (BD OptEIA Mouse IL-2 ELISA set, BD)
according to the manufacturer’s protocol. The media was replaced
with fresh cDMEM and the cultures were allowed to incubate for
three more days. T cell proliferation was then analyzed by CFSE
dilution.
ELISPOT
Millipore MultiScreen® Filter Plates (Millipore) were pretreated
according to the manufacturer’s instructions using the Mouse
IFNg ELISPOT kit (Mabtech). Bead isolated CD4 and CD8 T cells
(CD4 T cell Isolation Kit II and CD8α Isolation Kit II, Miltenyi)
were cultured as above (see Intracellular Cytokine Staining/Flow
Cytometry) with MUC1 pulsed BMDC and analyzed according to
the established protocol. DC alone, media alone, and T cells alone
were used to establish background cytokine production.
STATISTICAL ANALYSIS
Where appropriate, statistical significance was determined by per-
forming an unpaired Student’s t -test. *Denotes a p-value <0.05
and **denotes a p-value of <0.01. When indicated, to allow for
pooling of data from multiple experiments, values have been trans-
formed to account for minor variations in instrument settings and
other potential sources of variation (i.e., minor batch to batch vari-
ance in DC vaccine prep, etc.). Briefly, all experimental values were
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FIGURE 1 | Splenic DC activation is suppressed as early as 4–8 h
post-vaccination with a self-, but not a foreign-antigen and correlated
with early IL-10 production in the spleens of these animals. WT (squares)
and MUC1.Tg mice (triangles) were vaccinated with MUC1p plus Poly-ICLC
via tail vein. Spleens were removed at indicated hours post-vaccination and
total splenic mRNA levels of trypsin 1 (A), carboxypeptidase B1 (CPB1) (B),
and IL-10 (C) were determined relative to the control gene HPRT. Values
shown represent expression relative to the baseline expression in mice of
that genotype (WT and MUC1.Tg) at 0 h post-vaccination. Data are
representative of three pooled mice were group per time point shown. Data
points show mean±SEM of three technical replicates and are representative
of two independent experiments.
divided by the mean value of the control group from the experi-
ment in which they were run. “Relative” values therefore represent
a standardized deviance from control.
RESULTS
IL-10 EXPRESSION IN THE SPLEEN IS INCREASED 4–8H
POST-VACCINATION WITH MUC1p AS SELF-ANTIGEN AND
CORRELATES WITH DC SUPPRESSION
In order to determine how quickly post-vaccination with a self-
versus a foreign-antigen DC phenotype and function begin to
diverge and to obtain a more accurate picture of what factors might
be responsible for supporting this divergence, we vaccinated intra-
venously WT and MUC1.Tg mice with the MUC1 100mer peptide
(MUC1p) admixed with the Poly-ICLC adjuvant. MUC1.Tg mice
express the human tumor antigen MUC1 under the control of
its endogenous promoter and therefore MUC1p is seen as a self-
antigen in these mice, whereas it is seen as a foreign-antigen in WT
animals. Mice were sacrificed 4, 6, 8, and 16 h post-vaccination and
the spleens removed for mRNA isolation and analysis. As early as
4 h post-vaccination, two newly discovered biomarkers of DC acti-
vation, trypsin 1 and CPB1 (12), were up-regulated in the spleens
of WT mice but suppressed in MUC1.Tg mice (Figures 1A,B).
In addition to differences in the levels of these enzymes, which
our previous study showed to be expressed only in DC and repre-
sentative of a larger cohort of “pancreatic” enzymes that robustly
activated DC expression, we also detected at this early-time point
higher levels of IL-10 mRNA in the spleens of vaccinated MUC1.Tg
mice compared to WT mice. At 24 h post-vaccination and later,
IL-10 production was at equal levels in self- and foreign-antigen
vaccinated mice (Figure 1C and data not shown).
DC FROM SPLEENS OF MUC1p (SELF-ANTIGEN)-VACCINATED MUC1.Tg
MICE ARE MORE SENSITIVE TO IL-10 THAN MUC1p
(FOREIGN-ANTIGEN)-VACCINATED WT MICE
The above data showing differences in IL-10 levels early post-
vaccination but no difference at 24 h and later would indicate
a modest and transient effect by IL-10 on DC. This was, how-
ever, inconsistent with our previous observations that functional
differences between DC post self-antigen versus foreign-antigen
vaccine were evident as late as 72 h post-vaccination (12). We
considered the possibility that the early action of IL-10 on DC,
along with other factors, might increase their sensitivity to IL-10
at the later-time points. To query this, DC were removed from the
spleens of WT and MUC1.Tg mice 24 h post MUC1p vaccination
and exposed to IL-10. As signaling through the IL-10R is known
to occur through a STAT3 intermediate, the sensitivity of DC to
IL-10 was assessed by phosphoflow, measuring phospho-STAT3
levels post ex vivo exposure to IL-10. As hypothesized, there was
a significant increase in the number of DC showing STAT3 phos-
phorylation as well as higher levels of pSTAT3 in the spleens of
MUC1p-vaccinated MUC1.Tg mice (Figures 2A–C) indicating
that DC in the spleens of MUC1.Tg mice are not only exposed
to more IL-10 early on, but are also more sensitive to it at the
later-time points.
IL-10R BLOCKADE INCREASES COSTIMULATORY MOLECULE
EXPRESSION ON DC FOLLOWING VACCINATION WITH MUC1p AS
SELF-ANTIGEN
Given the inverse correlation between IL-10 production and DC
pancreatic enzyme expression in the first 24 h following vaccina-
tion and previously published data showing that IL-10 is necessary
for suppression of trypsin 1 and CPB1 following vaccination with
a self-antigen (12), we hypothesized that blocking IL-10 signaling
in self-antigen vaccinated mice would improve DC activation and
costimulatory molecule expression. We injected MUC1.Tg mice
with an antibody against IL-10R and vaccinated intravenously 24–
48 h later with MUC1p plus Poly-ICLC. At 24 h post-vaccination,
the surface phenotype of splenic DC was analyzed by flow cytome-
try. As hypothesized, there was an increase in the level of cell surface
expression of CD40, CD80, and CD86 in DC from mice pretreated
with the antibody to IL-10R, but not from mice treated with the
isotype control antibody (Figures 3A–C). Increases in CD40 and
CD86 were statistically significant, which is of interest because
these two molecules were shown previously to be specifically inhib-
ited in mice vaccinated with a self- but not a foreign-antigen (12).
In addition to being less active as measured by surface marker
expression, these DC are also less capable of stimulating MUC1
specific CD4 T cells in vitro. DC isolated from MUC1.Tg mice
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FIGURE 2 | Dendritic cell from spleens of mice vaccinated with
self-antigen have higher levels of phosphorylated STAT3 after IL-10
treatment than DC from spleens of mice vaccinated with
foreign-antigen. WT (solid line) and MUC1.Tg (dashed line) mice were
vaccinated with MUC1p via the tail vein. Twenty-four hours post-vaccination
splenocytes were removed and treated with 30 ng/mL of IL-10 for 20 min.
Following incubation, cells were fixed and phospho-STAT3 expression in
CD11c+NK1.1− splenocytes was analyzed via phoshpoflow.
(A) A representative flow plot is shown. The shaded histogram represents
the fluorescence level when cells are treated with standard surface markers
and an isotype-matched control instead of the phosphospecific antibody.
pSTAT3 positivity (B) and MFI (C) were analyzed. In (B) symbols correspond
to individual animals and are representative of two independent
experiments. (C) Values shown have been normalized to the expression
level of the control group (WT) in order to allow for pooling of data from
separate experiments run on multiple days. Bars are representative of nine
mice from two combined experiments and show the mean±SEM.
*Indicates a p-value of <0.05.
pretreated with an antibody against the IL-10R prior to MUC1
vaccination and put into culture with MUC1 specific CD4 T cells
induce higher levels of IL-2 (Figure 4A) and CD4 T cell prolif-
eration (Figures 4B,C) compared to DC from MUC1.Tg mice
pretreated with an isotype-matched control antibody.
BLOCKING IL-10 SIGNALING PRIOR TO VACCINATION WITH MUC1p AS
SELF-ANTIGEN IMPROVES CD4 T CELL RESPONSE
The increase of costimulatory molecule expression when IL-10
signaling was blocked just prior to vaccination suggested that
there would be a resultant increase in the T cell response. To
test this, we again pretreated mice with an anti-IL-10R antibody
or an isotype-matched control and injected with a vaccine com-
posed of DC loaded with MUC1p. We chose the DC-based vaccine
expecting that it would optimally stimulate both CD4 and CD8 T
cells, as has been previously shown (16). Seven to nine days post-
vaccination, splenic T cells were isolated and their production of
relevant cytokines analyzed by ELISPOT and intracellular flow
cytometry. In MUC1.Tg mice treated with anti-IL-10R, there was
a significant increase in MUC1p specific, IFNγ+CD4 T cells when
compared to mice treated with an isotype-matched control anti-
body (Figures 5A,C). The level of the response was equivalent to
the response of WT mice pretreated with the isotype control anti-
body (Figure 5A). There was no increase over the isotype control
of the T cell response in WT mice pretreated with the anti-IL-10R
antibody (Figures 5A,C), indicating that the effect of IL-10 we saw
in MUC1.Tg mice was specific for controlling responses to self-
but not foreign-antigens. There was a small but not significant
increase in the CD8 response that was detectable only by the more
sensitive ELISPOT (Figures 5B,D).
DISCUSSION
Vaccines against cancer have garnered a lot of attention in recent
years. Much of this was sparked by the relatively recent approval
of Sipuleucel-T, the first vaccine to show survival benefit in a solid
metastatic tumor (17, 18). Implementation of Gardasil®, a quadri-
valent human papilloma virus specific vaccination intended to
prevent cervical cancer in women (19, 20) has also sparked new
efforts in designing prophylactic cancer vaccines not just for viral
cancers but for many tumor types (21–24). Most non-viral tumor
antigens fall into the category of self- or altered self-antigens.
Mounting an effective immune response against them represents
a unique challenge. One must design vaccines that overcome the
natural tolerizing forces acting on responses to self-antigens, while
minimizing adverse autoimmune effects.
Our work with the MUC1 tumor antigen in the MUC1.Tg
mouse model system has shown that hyporesponsiveness to the
MUC1 peptide vaccines in these mice is neither due to the elimi-
nation of MUC1 peptide-specific T cells by central tolerance, nor
solely to their conditioning in the periphery, but rather by the
control of their activation (15). Indeed, even when unconditioned
MUC1 specific T cells are transferred into MUC1.Tg hosts, they
are hyporesponsive to MUC1 peptide vaccination but respond vig-
orously in WT hosts. Most recently, we determined that the major
reason for the lack of T cell response is profound, albeit transient,
tolerization of DC in MUC1p-vaccinated MUC1.Tg mice early
post-vaccination (12). Here, we show that this is likely due to the
very early and exaggerated effect of IL-10 on these DC in the first
4–24 h post-vaccination. IL-10 is known to reduce MHC Class II
and costimulatory molecule expression on DC (4–6), DC motility
(25, 26), and overall T cell stimulatory capacity (27, 28), all
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FIGURE 3 | Pretreatment with an antibody against the IL-10
receptor increases the level of costimulatory molecule expression
on DC in the spleens of self-antigen vaccinated mice. MUC1.Tg
mice were pretreated with an antibody against the IL-10 receptor
(IL-10R, solid lines) or were given a non-specific isotype control (iso,
dashed lines). One to two days later they were vaccinated as in
Figure 1 and 24 h post-vaccination, splenocytes were removed and
analyzed via flow cytometry. The expression level of CD40 (A), CD86
(B), and CD80 (C) on splenic DC (CD11C+, MHC Class II+) was
determined. Shaded histograms represent fluorescence in samples
stained with isotype alone. Bar graph values shown have been
normalized to the expression level of the control group (iso) in order to
allow for pooling of data from separate experiments run on multiple
days. (A,C) Data are combined from two independent experiments and
representative of six mice. (B) Data are combined from three
independent experiments and are representative of 10 mice. Bars
represent mean±SEM. p-Values are as stated unless designated by a
*, which indicates a p-value of <0.05.
FIGURE 4 | Blocking of the IL-10 receptor prior to intravenous MUC1
peptide vaccination increases the ability of splenic DC from MUC1.Tg
mice to stimulate MUC1 specific CD4T cells ex vivo. MUC1.tg mice
were treated as in Figure 3. Twenty-four hours post MUC1 vaccination,
splenocytes from three to four mice per treatment group were pooled and
bead isolated DC from these pooled splenocytes were put into culture with
CFSE labeled MUC1 specific CD4 T cells (VFT cells) at a ratio 1DC:5VFT.
Twenty-four hours after the start of culture, half of the culture media was
removed and the concentration of IL-2 was measured by ELISA (A).
Cultures were allowed to incubate three more days for a total of four and
VFT proliferation was analyzed by CFSE dilution (B,C). (B) Bars represent
the mean percentage of CD3+CD4+T cells that had proliferated at 4 days
of three technical replicates ±SEM. (C) A representative flow plot is shown.
Data are representative of two to three independent experiments.
*Indicates a p-value of <0.05.
of which are characteristics of DC in the spleens of MUC1p-
vaccinated MUC1.Tg mice (12).
The effects of IL-10 on vaccines have been observed previously.
In the therapeutic setting, IL-10R blockade alone or along with
vaccination can improve Th1 responses and enhance pathogen
clearance (29–31). In a prophylactic setting, mice given the BCG
vaccination for prevention of Mycobacterium tuberculosis show
improved Th1 responses and enhanced resistance to pathogen
challenge when IL-10R is blocked at the time of vaccination (32).
In this paper, we describe a distinct new role for IL-10 in impacting
vaccine outcome that is unique in its specificity for self-antigen.
The same MUC1 peptide, given as a self-antigen to MUC1.Tg mice
but as a foreign-antigen to WT mice, causes only low levels IL-10
production in WT mice and increased production in MUC1.Tg
mice. In previously published studies showing improvement in
immune responses after IL-10R blockade, IL-10 was produced
in response to acute or persistent pathogen infections, whereas
in this case it was specifically triggered in response to the pres-
ence of a self-antigen or specifically inhibited in the presence of a
foreign-antigen.
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FIGURE 5 |Treatment with anti-IL-10R antibody at the time of
vaccination increases the number of MUC1p specific, IFNγ+ CD4T cells
without an effect on CD8T cells. WT and MUC1.Tg mice were pretreated
with an antibody against the IL-10 receptor (IL-10R, black bars) or a
non-specific isotype control (iso, gray bars). One to two days following
antibody treatment, mice were vaccinated with DC loaded with MUC1p.
Seven to nine days post-vaccination, spleens were removed and bead
isolated CD4 (A,C) and CD8 T cells (B,D) were cultured with MUC1p loaded
bone marrow derived DC overnight and analyzed by ELISPOT (A,B), or were
cultured for 6–8 h in the presence of brefeldin-A and analyzed by intracellular
flow cytometry (C,D). (A) Data are combined from two independent
experiments with each spot indicating an individual animal. Data are
representative of three independent experiments. (B) Bars indicate the
average of three technical replicates pooled from three individual animals
per group. Data are representative of two independent experiments. (C,D)
Values shown are normalized to the response of mice of that genotype (WT
versus MUC1.Tg) given the control treatment (iso). Data are combined from
two independent experiments and are representative of five to six mice per
group. Bars represent mean±SEM. *Indicates a p-value of <0.05;
**indicates a p-value of <0.005.
We have yet to identify the source in the spleen of this early
IL-10 production in self-antigen vaccinated mice. Every cell of
the immune system can produce IL-10 given proper stimulation.
However the kinetics and pattern of IL-10 production in MUC1p-
vaccinated MUC1.Tg mice limits the possibilities considerably.
The fact that IL-10 production was antigen dependent suggests a
cell of the adaptive immune system. Regulatory T cells have previ-
ously been shown to be important in preventing MUC1p specific
immune responses in MUC1.Tg mice (12, 33). However, prelim-
inary experiments have been unable to identify IL-10 producing
regulatory T cells in MUC1.Tg mice at rest or immediately fol-
lowing vaccination (data not shown), as has been shown in some
models after self-peptide administration (34). Given that regula-
tory T cells can modulate the function of a wide variety of innate
cells, including NK cells (35, 36) and DCs (37, 38), it is possible
that through secretion of another cytokine or through direct inter-
actions, they induce IL-10 production either directly or indirectly
in another cell population.
Irrespective of the source, the self-antigen specific role of IL-
10 reported in this paper supports IL-10 inhibition as a way
of improving the efficacy of vaccines against self-antigens that
are candidate tumor antigens. While our major success in this
study was in improving CD4 T cell responses, we would hypoth-
esize that CD8 T cell responses generated upon boosting would
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be improved as well in these animals as a consequence of gen-
eration of a larger population of helper CD4 T cells that are
required for effective CD8 T cell memory differentiation (39, 40).
The concern remains that any manipulation leading to enhanced
responses to self/tumor antigens might cause adverse autoimmune
reactions. However, current research has shown this concern can
be addressed by proper antigen selection. For example, vaccines
against self/tumor antigens MUC1 and α-lactalbumin have shown
clinical and preclinical efficacy with no induction of autoimmu-
nity (23, 41, 42). And vitiligo, caused by successful anti-melanoma
vaccines is an autoimmune event that can be easily tolerated (43–
45). Furthermore, while long term IL-10 deficiency can cause
adverse autoimmune effects (46, 47), our data suggest that in order
to improve the vaccine response, IL-10 would need to be blocked
only transiently at the time of initial vaccination.
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